Clinical Trials Directory

Trials / Conditions / Castleman Disease

Castleman Disease

12 registered clinical trials studyying Castleman Disease — 5 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingNintedanib Treatment in Unicentric Castleman Disease
NCT06643091
Assistance Publique - Hôpitaux de ParisPhase 2
RecruitingAn Italian Multicenter Retrospective Observational Study to Assess Effectiveness and Safety of Siltuximab for
NCT06720870
IRCCS Azienda Ospedaliero-Universitaria di Bologna—
RecruitingHHV8 and Solid Organ Transplantation
NCT05081141
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico—
RecruitingAutoInflammatory Disease Alliance Registry (AIDA)
NCT05200715
University of Siena—
Active Not RecruitingSirolimus in Previously Treated Idiopathic Multicentric Castleman Disease
NCT03933904
University of PennsylvaniaPhase 2
RecruitingInternational Registry for Patients With Castleman Disease
NCT02817997
University of Pennsylvania—
WithdrawnCastleman Disease Collaborative Network Biobank
NCT02871050
Castleman Disease Collaborative Network—
CompletedUnlock the Cell: Castleman's Disease Flow Cytometry Study
NCT02853968
University of Pennsylvania—
TerminatedNelfinavir for the Treatment of Gammaherpesvirus-Related Tumors
NCT02080416
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsEARLY_Phase 1
Active Not RecruitingBevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With
NCT01552434
M.D. Anderson Cancer CenterPhase 1
CompletedTocilizumab for KSHV-Associated Multicentric Castleman Disease
NCT01441063
National Cancer Institute (NCI)Phase 2
CompletedUnicentric Form of Castleman Disease - Surgery Therapy Benefit
NCT05440305
Charles University, Czech Republic—